However, the effect of ITGB3BP on the immune microenvironment in GBM is relatively limited compared with that in LGG, probably because of the large amount of heterogeneity between GBM and LGG, although both are glioma subtypes. This evidence concerns the gene ITGB3BP and central nervous system cancer.